Anthera Pharmaceuticals Inc (ANTH) : Sio Capital Management scooped up 1,677,753 additional shares in Anthera Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,056,196 shares of Anthera Pharmaceuticals Inc which is valued at $9,382,522.Anthera Pharmaceuticals Inc makes up approximately 4.21% of Sio Capital Management’s portfolio.
Other Hedge Funds, Including , Panagora Asset Management Inc sold out all of its stake in ANTH during the most recent quarter. The investment firm sold 13,341 shares of ANTH which is valued $40,957.Tiaa Cref Investment Management boosted its stake in ANTH in the latest quarter, The investment management firm added 3,747 additional shares and now holds a total of 212,457 shares of Anthera Pharmaceuticals Inc which is valued at $652,243.Hightower Advisors boosted its stake in ANTH in the latest quarter, The investment management firm added 3,700 additional shares and now holds a total of 50,100 shares of Anthera Pharmaceuticals Inc which is valued at $153,807.Hilltop Park Associates boosted its stake in ANTH in the latest quarter, The investment management firm added 10,000 additional shares and now holds a total of 75,000 shares of Anthera Pharmaceuticals Inc which is valued at $225,750. Anthera Pharmaceuticals Inc makes up approx 3.17% of Hilltop Park Associates’s portfolio.
Anthera Pharmaceuticals Inc opened for trading at $2.9 and hit $2.94 on the upside on Thursday, eventually ending the session at $2.91, with a gain of 1.04% or 0.03 points. The heightened volatility saw the trading volume jump to 2,85,309 shares. Company has a market cap of $121 M.
Many Wall Street Analysts have commented on Anthera Pharmaceuticals Inc. H.C. Wainwright Initiated Anthera Pharmaceuticals Inc on Jul 8, 2016 to “Buy”, Price Target of the shares are set at $10.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Company’s second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.